{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:34Z","timestamp":1792481134592,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Omadacycline is a newly launched drug of tetracycline. Therefore, it is necessary to comprehensive evaluate reports on the safety of omadacycline in large, real-world populations. This study aimed to mine the adverse event (AE) signals related to omadacycline through the Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the FAERS database from 1 January 2004 and 31 March 2024 were queried through OpenVigil 2.1. After the completion of data mapping, we collated and summarized key demographic and clinical characteristics of the reported cases. During the analysis, both Reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) were employed for the detection of AE signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We extracted a total of 452 suspected AE cases with omadacycline from the FAERS database. Among them, 69 positive signals were obtained using the ROR and BCPNN. The highest frequency reported systemic organ class (SOC) was gastrointestinal disorders. Common clinical AEs of omadacycline were detected in the FAERS database, such as nausea, vomiting, tongue discolouration, hepatic enzyme increased, and hypersensitivity. In addition, we identified potential unexpected serious AEs through disproportionality analysis, including eosinophilia, pancytopenia, internal haemorrhage, restless legs syndrome, hypoacusis, and tinnitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In light of the growing use of omadacycline in clinical practice, routinely reviewing data from the FAERS database for signals of AE can help to ensure patient medication safety and enhance overall medical quality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1558868","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:53:04Z","timestamp":1743486784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueping","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil--free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens","volume":"62","author":"Bundrant","year":"2018","journal-title":"Antimicrob. agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2147\/IDR.S171352","article-title":"Omadacycline: a novel aminomethylcycline","volume":"12","author":"Burgos","year":"2019","journal-title":"Infect. drug Resist."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/cid\/ciac128","article-title":"Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis","volume":"75","author":"Chuma","year":"2022","journal-title":"Clin. Infect. Dis. official Publ. Infect. Dis. Soc. Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob. agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1128\/AAC.01536-15","article-title":"Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline","volume":"59","author":"Honeyman","year":"2015","journal-title":"Antimicrob. agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J. allergy Clin. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40264-016-0413-1","article-title":"Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from Vigibase(\u00ae)","volume":"39","author":"Montastruc","year":"2016","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.15036\/arerugi.65.200","article-title":"A case of anaphylaxis in the pediatric patient with milk allergy due to traces of milk protein in the lactose used as an excipient of inavir inhalation","volume":"65","author":"Morikawa","year":"2016","journal-title":"Arerugi = Allergy"},{"key":"B12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/B978-0-12-387817-5.00026-1","article-title":"Chapter 26 - hepatotoxicity of antimicrobials and antifungal agents","volume-title":"Drug-induced liver disease","author":"Moseley","year":"2013"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S40-S47","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin. Infect. Dis. official Publ. Infect. Dis. Soc. Am."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"","journal-title":"Lancet Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O'Riordan","year":"","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083-18","article-title":"Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1b study","volume":"63","author":"Overcash","year":"2019","journal-title":"Antimicrob. agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1128\/AAC.00320-16","article-title":"In vitro and in vivo assessments of cardiovascular effects with omadacycline","volume":"60","author":"Tanaka","year":"2016","journal-title":"Antimicrob. agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00018-009-0172-6","article-title":"The tetracycline resistome","volume":"67","author":"Thaker","year":"2010","journal-title":"Cell. Mol. life Sci. CMLS"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1182113","DOI":"10.3389\/fphar.2023.1182113","article-title":"Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1558868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:53:11Z","timestamp":1743486791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1558868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":21,"alternative-id":["10.3389\/fphar.2025.1558868"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1558868","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1558868"}}